Business
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference - GERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ --
About this update from Precigen, Inc.
[{"type":"text","content":"- Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference -\n\n\nGERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 3:40 PM ET. \n\n \n \n \n \n \n \n\n \nDr. Sabzevari will also participate in a panel discussion hosted by Scott Gottlieb, MD, at the H.C. Wainwright BioConnect 2021 Conference on January 13, 2021 at 12:00 PM ET. The panel will explore precision medicine and the importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.\nParticipants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.\nPrecigen: Advancing Medicine with Precision™Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.\nCautionary Statement Regarding Forward-Looking StatementsSome of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio...